Does the media favor ETON or HUMA?

In the previous week, Eton Pharmaceuticals had 6 more articles in the media than Humacyte. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 4 mentions for Humacyte. Humacyte's average media sentiment score of 0.86 beat Eton Pharmaceuticals' score of 0.20 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, PHAR or HUMA?

Pharming Group has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharming Group $369.49M 2.34 $2.85M $0.16 76.38 Humacyte $2.02M 154.18 -$40.83M -$0.57 N/A

Is PHAR or HUMA more profitable?

Pharming Group has a net margin of 3.30% compared to Humacyte's net margin of -4,836.06%. Pharming Group's return on equity of 4.64% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Pharming Group 3.30% 4.64% 2.55% Humacyte -4,836.06% -2,914.18% -89.45%

Does the media prefer PHAR or HUMA?

In the previous week, Pharming Group had 2 more articles in the media than Humacyte. MarketBeat recorded 6 mentions for Pharming Group and 4 mentions for Humacyte. Humacyte's average media sentiment score of 0.86 beat Pharming Group's score of 0.23 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ANNX or HUMA?

Humacyte has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Humacyte $2.02M 154.18 -$40.83M -$0.57 N/A

Is ANNX or HUMA more profitable?

Annexon has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Annexon's return on equity of -101.19% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Humacyte -4,836.06% -2,914.18% -89.45%

Does the media refer more to ANNX or HUMA?

In the previous week, Annexon and Annexon both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Humacyte's score of 0.86 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Humacyte (HUMA) Competitors

$1.40 +0.01 (+0.72%)

As of 01:04 PM Eastern

Compare

HUMA vs. PHAT, ETON, PHAR, JANX, and ANNX

Should you buy Humacyte stock or one of its competitors? MarketBeat compares Humacyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Humacyte include Phathom Pharmaceuticals (PHAT), Eton Pharmaceuticals (ETON), Pharming Group (PHAR), Janux Therapeutics (JANX), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry.

How does Humacyte compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Humacyte has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.57	-$221.25M	-$2.12	N/A
Humacyte	$2.02M	154.18	-$40.83M	-$0.57	N/A

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Humacyte had 3 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 4 mentions for Humacyte and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.87 beat Humacyte's score of 0.86 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Very Positive
Humacyte	Positive

Phathom Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

Phathom Pharmaceuticals has a net margin of -76.77% compared to Humacyte's net margin of -4,836.06%. Phathom Pharmaceuticals' return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Phathom Pharmaceuticals presently has a consensus price target of $25.00, suggesting a potential upside of 149.00%. Humacyte has a consensus price target of $6.43, suggesting a potential upside of 359.18%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Phathom Pharmaceuticals beats Humacyte on 9 of the 17 factors compared between the two stocks.

How does Humacyte compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Eton Pharmaceuticals presently has a consensus target price of $41.00, suggesting a potential upside of 50.74%. Humacyte has a consensus target price of $6.43, suggesting a potential upside of 359.18%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Eton Pharmaceuticals had 6 more articles in the media than Humacyte. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 4 mentions for Humacyte. Humacyte's average media sentiment score of 0.86 beat Eton Pharmaceuticals' score of 0.20 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has higher revenue and earnings than Humacyte. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	9.32	-$4.60M	-$0.07	N/A
Humacyte	$2.02M	154.18	-$40.83M	-$0.57	N/A

Eton Pharmaceuticals has a net margin of -1.70% compared to Humacyte's net margin of -4,836.06%. Eton Pharmaceuticals' return on equity of -5.68% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Eton Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

Summary

Eton Pharmaceuticals and Humacyte tied by winning 8 of the 16 factors compared between the two stocks.

How does Humacyte compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pharming Group currently has a consensus target price of $38.33, suggesting a potential upside of 213.69%. Humacyte has a consensus target price of $6.43, suggesting a potential upside of 359.18%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Pharming Group has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, suggesting that its stock price is 145% more volatile than the broader market.

In the previous week, Pharming Group had 2 more articles in the media than Humacyte. MarketBeat recorded 6 mentions for Pharming Group and 4 mentions for Humacyte. Humacyte's average media sentiment score of 0.86 beat Pharming Group's score of 0.23 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has higher revenue and earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.34	$2.85M	$0.16	76.38
Humacyte	$2.02M	154.18	-$40.83M	-$0.57	N/A

Pharming Group has a net margin of 3.30% compared to Humacyte's net margin of -4,836.06%. Pharming Group's return on equity of 4.64% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Summary

Pharming Group and Humacyte tied by winning 8 of the 16 factors compared between the two stocks.

How does Humacyte compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Janux Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Janux Therapeutics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Janux Therapeutics' return on equity of -12.93% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-12.93%	-12.23%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Janux Therapeutics currently has a consensus price target of $45.85, indicating a potential upside of 236.86%. Humacyte has a consensus price target of $6.43, indicating a potential upside of 359.18%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.60
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Humacyte has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$13.73M	60.44	-$113.62M	-$1.84	N/A
Humacyte	$2.02M	154.18	-$40.83M	-$0.57	N/A

In the previous week, Humacyte had 3 more articles in the media than Janux Therapeutics. MarketBeat recorded 4 mentions for Humacyte and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.29 beat Humacyte's score of 0.86 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Janux Therapeutics	Positive
Humacyte	Positive

Summary

Janux Therapeutics beats Humacyte on 10 of the 17 factors compared between the two stocks.

How does Humacyte compare to Annexon?

Annexon (NASDAQ:ANNX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Annexon and Annexon both had 4 articles in the media. Annexon's average media sentiment score of 1.29 beat Humacyte's score of 0.86 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

44.7% of Humacyte shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 3.1% of Humacyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Annexon currently has a consensus target price of $16.00, indicating a potential upside of 201.89%. Humacyte has a consensus target price of $6.43, indicating a potential upside of 359.18%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Annexon has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Annexon's return on equity of -101.19% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

Annexon has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

Humacyte has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Humacyte	$2.02M	154.18	-$40.83M	-$0.57	N/A

Summary

Humacyte beats Annexon on 9 of the 14 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HUMA vs. The Competition

Export

Metric	Humacyte	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$310.83M	$3.26B	$6.26B	$12.44B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	-2.46	17.75	22.35	24.23
Price / Sales	154.18	323.71	555.60	126.08
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	70.00	6.55	9.82	6.73
Net Income	-$40.83M	$24.20M	$3.56B	$336.97M
7 Day Performance	21.74%	-3.25%	-1.16%	0.79%
1 Month Performance	63.69%	0.48%	3.85%	5.38%
1 Year Performance	-46.36%	47.06%	27.33%	34.55%

Humacyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HUMA Humacyte	3.8687 of 5 stars	$1.40 +0.7%	$6.43 +359.2%	-46.9%	$310.83M	$2.02M	N/A	150	Analyst Forecast Gap Up
PHAT Phathom Pharmaceuticals	2.7214 of 5 stars	$11.33 flat	$25.00 +120.7%	+108.0%	$903.64M	$175.11M	N/A	110	Gap Up
ETON Eton Pharmaceuticals	4.4369 of 5 stars	$32.59 flat	$41.00 +25.8%	+45.4%	$892.71M	$79.95M	N/A	20	Gap Up
PHAR Pharming Group	3.7836 of 5 stars	$12.60 flat	$38.33 +204.2%	+7.0%	$889.88M	$376.13M	78.75	280	Positive News Gap Up
JANX Janux Therapeutics	3.5383 of 5 stars	$14.52 flat	$45.85 +215.7%	-44.9%	$885.49M	$10M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HUMA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humacyte (HUMA) Competitors

HUMA vs. PHAT, ETON, PHAR, JANX, and ANNX

How does Humacyte compare to Phathom Pharmaceuticals?

Summary

How does Humacyte compare to Eton Pharmaceuticals?

Summary

How does Humacyte compare to Pharming Group?

Summary

How does Humacyte compare to Janux Therapeutics?

Summary

How does Humacyte compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Humacyte (HUMA) Competitors

HUMA vs. PHAT, ETON, PHAR, JANX, and ANNX

How does Humacyte compare to Phathom Pharmaceuticals?

Which has higher earnings and valuation, PHAT or HUMA?

Do institutionals and insiders have more ownership in PHAT or HUMA?

Does the media prefer PHAT or HUMA?

Which has more risk and volatility, PHAT or HUMA?

Is PHAT or HUMA more profitable?

Do analysts recommend PHAT or HUMA?

Summary

How does Humacyte compare to Eton Pharmaceuticals?

Do analysts prefer ETON or HUMA?

Does the media favor ETON or HUMA?

Which has stronger earnings and valuation, ETON or HUMA?

Is ETON or HUMA more profitable?

Do insiders and institutionals hold more shares of ETON or HUMA?

Which has more volatility & risk, ETON or HUMA?

Summary

How does Humacyte compare to Pharming Group?

Do insiders & institutionals have more ownership in PHAR or HUMA?

Do analysts recommend PHAR or HUMA?

Which has more risk & volatility, PHAR or HUMA?

Does the media prefer PHAR or HUMA?

Which has stronger valuation & earnings, PHAR or HUMA?

Is PHAR or HUMA more profitable?

Summary

How does Humacyte compare to Janux Therapeutics?

Which has more risk and volatility, JANX or HUMA?

Do institutionals & insiders believe in JANX or HUMA?

Is JANX or HUMA more profitable?

Do analysts recommend JANX or HUMA?

Which has higher earnings & valuation, JANX or HUMA?

Does the media prefer JANX or HUMA?

Summary

How does Humacyte compare to Annexon?

Does the media refer more to ANNX or HUMA?

Do insiders & institutionals hold more shares of ANNX or HUMA?

Do analysts recommend ANNX or HUMA?

Is ANNX or HUMA more profitable?

Which has more risk & volatility, ANNX or HUMA?

Which has better valuation & earnings, ANNX or HUMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUMA vs. The Competition

Humacyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools